ThermoGenesis Holdings, Inc. (THMO) has experienced an increase of 7.58% in the aftermarket. However, the last trading session closed at $1.98 with an incline of 0.51%.
Automated manufacturing of Gene-engineered Autologous Cell (GEAC) Therapies
THMO reported on 14th September 2021 that it has received a $250,000 Phase I SBIR funding. The funding is meant to design and test the single-use sterile cell processing disposable. These programs enable US-owned life science firms to participate in government research and development with a high potential for commercialization that aligns with the NIH’s objective of improving health and saving lives.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Existing X-Series cartridges have been shown to concentrate mononuclear cells from blood with target cell recovery efficiencies of 90-100 percent (for T cells and hematopoietic stem cells), as well as to wash or volume-reduce cell solutions with the same success. Likewise, X-BACS reagents found in X-Series cartridges are up to 50% more efficient than conventional ferrous bead/magnetic field techniques for high-purity target cell separation.
Second Quarter 2021 Financial Results
THMO announced second quarter 2021 results on 5th August 2021. Firstly, THMO had net revenues of $2.2 million. When compared to the same quarter in 2020, AXP sales increased by $0.4 million while BioArchive sales increased by $0.1 million. Secondly, this is a good indication, since it shows that cord blood revenues are beginning to recover after the epidemic.
Thirdly, selling, general, and administrative costs were $3.5 million more than the previous quarter. The increase was largely attributable to accelerated expenditure for stock options which increased by about $1.6 million. Lastly, research and development costs were $0.6 million, compared to $0.6 million for the quarter ended June 30, 2020.
THMO announces First Quarter 2021 Financial Results
On 13th May 2021, THMO reported first quarter 2021 financial results. Firstly, net revenues were $1.5 million, down from $3.2 million in the previous quarter. AXP disposable sales fell $1.9 million in the first quarter of 2021. The COVID-19 pandemic was the principal cause of the drop. Secondly, gross profit was $0.7 million down from $1.5 million. Thirdly, The drop was due to the lack of legal and other expenditures of about $0.2 million connected to the Mavericks. Lastly, increased stock compensation expenditure of $164,000 negated these savings in the current quarter.
